Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

NCT04692415 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Degludec
DRUG: Glargine U300

Sponsor

University of Split, School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]